Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TLC C 53

Drug Profile

TLC C 53

Alternative Names: LIP-PGE1; Ventus

Latest Information Update: 02 Aug 2002

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Liposome Company
  • Developer Taisho Pharmaceutical; The Liposome Company
  • Class Prostaglandins
  • Mechanism of Action Platelet aggregation inhibitors; Prostaglandin E1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Coronary artery restenosis; Cystic fibrosis; Inflammation; Myocardial infarction; Peripheral vascular disorders; Septic shock; Systemic inflammatory response syndrome; Thrombosis
  • Discontinued Adult respiratory distress syndrome

Most Recent Events

  • 31 May 2000 The Liposome Company has been acquired by Elan Corporation
  • 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in European Union (Unknown route)
  • 16 Sep 1998 Discontinued-II for Adult respiratory distress syndrome in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top